NCT04791059 is a Phase 4 clinical trial of S-ketamine in Scoliosis Correction, sponsored by Peking University First Hospital.

Who is sponsoring NCT04791059?

NCT04791059 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT04791059?

Interventions in NCT04791059: S-ketamine, Dexmedetomidine, Sufentanil.

What condition does NCT04791059 study?

NCT04791059 studies Scoliosis Correction, Postoperative Analgesia, S-ketamine, Dexmedetomidine, Sufentanil.

Is NCT04791059 still recruiting?

NCT04791059 is currently completed. Last updated 13 December 2022.

Last reviewed 2022-12-13 · How we verify

NCT04791059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia

Completed Phase 4 Last updated 13 December 2022

What this trial tests

Phase 4 trial testing S-ketamine in Scoliosis Correction in 200 participants. Completed in 7 October 2022.

Timeline

9 April 2021

Primary endpoint
7 September 2022

7 October 2022

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	200
Start date	9 April 2021
Primary completion	7 September 2022
Estimated completion	7 October 2022
Sites	1 location across China

Drugs / interventions tested

S-ketamine
Dexmedetomidine (dexmedetomidine) — full drug profile →
Sufentanil (SUFENTANIL) — full drug profile →

Conditions studied

Scoliosis Correction — all drugs for Scoliosis Correction →
Postoperative Analgesia — all drugs for Postoperative Analgesia →
S-ketamine — all drugs for S-ketamine →
Dexmedetomidine — all drugs for Dexmedetomidine →

Sponsor

Peking University First Hospital

Who can join

18 and older, any sex, with Scoliosis Correction or Postoperative Analgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Scoliosis correction surgery is followed with severe pain. Patients after scoliosis correction surgery usually require high dose opioids and long duration analgesia, which may increase side effects and even drug tolerance. S-ketamine is the pure dextrorotatory enantiomer of ketamine with stronger analgesic effect and less side effects, but mental side effects is a major concern. Dexmedetomidine can be used as an analgesic supplement; it also improves sleep quality in postoperative patients. We hypothesize that low-dose ketamine and dexmedetomidine in combination with opioids may have synergistic effect in analgesia and reduce drug-related side effects. This study aims to explore the effect of low-dose of S-ketamine and dexmedetomidine in combination with opioids for postoperative patient-controlled intravenous analgesia in patients following scoliosis correction surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mini-dose esketamine-dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial.
Zhang Y, Cui F, Ma JH, Wang DX. · · 2023 · cited 47× · PMID 37302963 · DOI 10.1016/j.bja.2023.05.001

Verify or expand the search:

Other trials of S-ketamine

Trials testing the same drug.

NCT05095857 — The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury · Phase 4 · recruiting
NCT05414006 — Effect of S-ketamine in Cesarean Section Combined Anesthesia · Phase 4 · completed
NCT05289050 — Analgesic Effect of Intraoperative Intravenous S-Ketamine During Total Knee Arthroplasty Surgery · Phase 4 · unknown
NCT05299866 — The Effect of S-ketamine Combined With Sufentanil for Postoperative Analgesia in Patients Following Cesarean Section · Phase 4 · unknown
NCT05242692 — The Effects of Subanesthetic S-ketamine on Postoperative Delirium and Cognitive Function in the Elderly Undergoing Non-c · EARLY_PHASE1 · completed

Other recruiting trials for Scoliosis Correction

Currently open trials in the same condition.

NCT07217873 — IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study · Phase 2, PHASE3 · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04791059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 13 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing